BIIB122 (DNL151)

TargetLRRK2

Modalitysmall molecule inhibitor

IndicationParkinson's disease

PhasePhase 2 (Completed)

PartnerBiogen

Trial IDNCT05348785

Notes

BIIB122 is a highly selective LRRK2 inhibitor. While mostly known for its role in neurons, LRRK2 is heavily expressed in microglia where it governs lysosomal degradation and neuroinflammation. Phase 2 trials evaluated the safety and slowing of early-stage PD.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 3, 2026